Empagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical)

恩格列净/二甲双胍/西格列汀 (Chong Kun Dang Pharmaceutical)

Report date: 2026/05/22 20:01:29

Base Information

Drug NameEmpagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical)

Drug Alias NameEmsiforminCKD-379

ClassificationSmall molecules

Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors

TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1Dipeptidyl peptidase IV

Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsYes Empagliflozin Metformin Hydrochloride Sitagliptin Phosphate Monohydrate

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesChong Kun Dang Pharmaceutical Corp

China Registration ClassN/A

Develop Information

Active CompaniesChong Kun Dang Pharmaceutical Corp

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

Inactive IndicationsN/A

Other Information

ATC CodeN/A